News & Partnerships

Press Releases

December 12, 2024

Sciwind’s Second Marketing Authorization Application of Ecnoglutide for Chronic Weight Management Has Been Accepted by the NMPA of China

November 24, 2024

Marketing Authorization Application for Ecnoglutide, a First-in-Class Biased GLP-1 Peptide Agonist, has Been Accepted by the NMPA of China

May 7, 2024

Sciwind Biosciences and HK inno.N Corporation Announce Licensing and Partnership Agreement for Ecnoglutide Injection (XW003) in South Korea

January 23, 2024

Sciwind Biosciences Announces Positive Results from Phase 1 Clinical Trial of XW004, an Oral Formulation of Long-acting GLP-1 Analog Ecnoglutide

January 2, 2024

Sciwind Biosciences Announces Positive Topline Results from Phase 3 Clinical Trial of Ecnoglutide (XW003), a Long-acting cAMP Signaling Biased GLP-1 Analog, in Adult Patients with Type 2 Diabetes in China

July 11, 2023

Sciwind Biosciences Announces Publication of Discovery, Preclinical, and Phase 1 Clinical Trial Results of Ecnoglutide (XW003) in Molecular Metabolism

June 23, 2023

Sciwind Biosciences to Highlight Positive Clinical Data for GLP-1 Peptide Agonist Ecnoglutide (XW003) at the American Diabetes Association (ADA) 83rd Annual Conference

January 30, 2023

Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 3 Clinical Trials of Ecnoglutide (XW003), a Long-acting GLP-1 analog, for the Treatment of Type 2 Diabetes in China

October 27, 2022

Sciwind Biosciences Announces Positive Interim Results from Ongoing Phase 2b Clinical Trial of XW003 (Ecnoglutide) in Patients with Obesity

October 9, 2022

Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW014, an oral small molecule GLP-1 receptor agonist for the Treatment of Obesity and Type 2 Diabetes

September 26, 2022

Sciwind Biosciences and SynerK Enter into Research Partnership to Discover and Develop Novel siRNA Therapeutics

August 8, 2022

Sciwind Biosciences Reports Positive Interim Results from Phase 1c/2a Clinical Trial of XW003 (Ecnoglutide) in Overweight and Obese Adult Volunteers in China

August 2, 2022

Sciwind Biosciences Announces Positive Topline Results from 20-week Phase 2 Clinical Trial of XW003 (Ecnoglutide), a novel long-lasting GLP-1 analogue, in Adult Patients with Type 2 Diabetes in China

June 8, 2022

Sciwind Biosciences to present Data from its GLP-1 and GIP Receptor Agonist Programs at The International Liver Congress(TM) EASL 2022

April 13, 2022

Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW004, an oral tablet formulation of its Proprietary GLP-1 Analogue (Ecnoglutide)

January 17, 2022

Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 2b Clinical Trial Evaluating XW003, its Lead GLP-1 Drug Candidate, for the Treatment of Obesity

December 9, 2021

Sciwind Biosciences Completes Enrollment in Phase 2 Clinical Trial of XW003 in Type 2 Diabetes Patients

November 30, 2021

Sciwind Biosciences Acquires Global, Exclusive Rights to Develop and Commercialize Sanofi's GIP Receptor Agonists for the Treatment of Metabolic Disease

October 12, 2021

Sciwind Biosciences Completes $70 Million Series C Financing and Expands Leadership Team to Advance Metabolic Disease Pipeline

July 11, 2021

Sciwind Biosciences Appoints Dr. Weidong Zhong as Chief Strategy Officer and President of its US Subsidiary

February 28, 2021

Sciwind's Investigational New Drug Approved for NASH Trial

February 18, 2021

Sciwind Biosciences Secures US$37 Million Series B Financing